Analysts Set Trevi Therapeutics, Inc. (NASDAQ:TRVI) Price Target at $9.31

Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) have been given an average recommendation of “Buy” by the ten ratings firms that are presently covering the company, Marketbeat.com reports. Eight equities research analysts have rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $9.31.

TRVI has been the topic of a number of research analyst reports. Leerink Partners started coverage on shares of Trevi Therapeutics in a research note on Monday, September 9th. They set an “outperform” rating and a $7.00 price objective on the stock. Needham & Company LLC restated a “buy” rating and set a $8.00 target price on shares of Trevi Therapeutics in a report on Thursday, December 12th. HC Wainwright raised their target price on shares of Trevi Therapeutics from $6.00 to $7.50 and gave the stock a “buy” rating in a report on Thursday, December 12th. Leerink Partnrs upgraded shares of Trevi Therapeutics to a “strong-buy” rating in a report on Monday, September 9th. Finally, B. Riley restated a “buy” rating and set a $6.00 target price on shares of Trevi Therapeutics in a report on Monday, October 7th.

Trevi Therapeutics Price Performance

NASDAQ TRVI opened at $4.32 on Thursday. Trevi Therapeutics has a 12 month low of $1.27 and a 12 month high of $4.68. The firm has a market capitalization of $332.06 million, a PE ratio of -9.82 and a beta of 0.87. The company’s 50 day simple moving average is $3.31 and its 200 day simple moving average is $3.10.

Trevi Therapeutics (NASDAQ:TRVI) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01). During the same quarter last year, the business posted ($0.08) EPS. Sell-side analysts anticipate that Trevi Therapeutics will post -0.49 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Trevi Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in TRVI. Ally Bridge Group NY LLC acquired a new position in Trevi Therapeutics in the 2nd quarter worth approximately $4,395,000. Logos Global Management LP boosted its stake in shares of Trevi Therapeutics by 27.3% during the 2nd quarter. Logos Global Management LP now owns 2,800,000 shares of the company’s stock valued at $8,344,000 after buying an additional 600,000 shares during the period. GSA Capital Partners LLP acquired a new stake in shares of Trevi Therapeutics during the 3rd quarter valued at $409,000. Geode Capital Management LLC boosted its stake in shares of Trevi Therapeutics by 10.2% during the 3rd quarter. Geode Capital Management LLC now owns 1,264,166 shares of the company’s stock valued at $4,223,000 after buying an additional 117,418 shares during the period. Finally, Fred Alger Management LLC acquired a new stake in shares of Trevi Therapeutics during the 3rd quarter valued at $256,000. Institutional investors and hedge funds own 95.76% of the company’s stock.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.